Why senolytic drugs aren't on the market yet - Prof. Alexandra Stolzing explains

🚀 FULL EPISODE HERE: https://www.youtube.com/watch?v=Nd_LktFpMMU&t=2160s 🚀 Detailed show notes are available in the LEVITY newsletter: https://peterottsjo.beehiiv.com/ 🚀 Don't forget to SUBSCRIBE to our channel: https://www.youtube.com/channel/UCQ2g_IsL0inKrkc6omolPdA?sub_confirmation=1 🚀 Looking for LEVITY Merch? https://levity-7.creator-spring.com/ Professor Alexandra Stolzing reveals the crucial obstacle in bringing senolytic drugs to market: the lack of effective biomarkers for senescent cells. She explains why current methods of detecting these cells in living organisms are inadequate, requiring invasive tissue sampling and staining. Prof. Stolzing discusses her research on senescent cell surface markers and how they could revolutionize the field, potentially enabling non-invasive detection methods like PET scans. Learn why developing these biomarkers is essential for streamlining clinical trials and bringing effective senolytic treatments to patients. #Senolytics #AgingResearch #Biomarkers